| Literature DB >> 33925299 |
Jana Krystofova Mike1, Donna Marie Ferriero1,2.
Abstract
Neonatal brain hypoxia-ischemia (HI) is a leading cause of morbidity and long-term disabilities in children. While we have made significant progress in describing HI mechanisms, the limited therapies currently offered for HI treatment in the clinical setting stress the importance of discovering new targetable pathways. Efferocytosis is an immunoregulatory and homeostatic process of clearance of apoptotic cells (AC) and cellular debris, best described in the brain during neurodevelopment. The therapeutic potential of stimulating defective efferocytosis has been recognized in neurodegenerative diseases. In this review, we will explore the involvement of efferocytosis after a stroke and HI as a promising target for new HI therapies.Entities:
Keywords: efferocytosis; neonatal brain; stroke
Year: 2021 PMID: 33925299 DOI: 10.3390/cells10051025
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600